← brief for 2026-09-10 · Slowing decline

A comparative real-world analysis of finerenone and steroidal mineralocorticoid receptor antagonists in patients with chronic kidney disease

Key takeaways

This study compares finerenone, a newer kidney and heart drug, with older drugs in the same family such as spironolactone. It uses real-world records of people with chronic kidney disease who were already taking these drugs, so it can show a link, not proof of cause. The full abstract was not available in this sweep, so how much better either drug did is not known yet.

Who did this work

Daniele Vetrano (University of Bologna) · Giuseppe Cianciolo (Istituti di Ricovero e Cura a Carattere Scientifico) · Simona Barbuto (Istituti di Ricovero e Cura a Carattere Scientifico) · Danilo Ribichini (Azienda Ospedaliero-Universitaria Careggi) · Sabrina Berti (Azienda Ospedaliero-Universitaria Careggi) · Anna Mistretta (University of Bologna) · Martina Ginesi (University of Bologna) · Phillip Timothy Millar (University of Bologna) · Amedeo Grimaldi (University of Bologna) · Gisella Vischini (Ospedale di Belcolle) · Elisabetta Poluzzi (University of Bologna) · Uberto Pagotto (Azienda Ospedaliero-Universitaria Careggi)

Source

Paper · OpenAlex, CKD works · 2026-09-09
https://doi.org/10.3389/fphar.2026.1918516